Budesonide for Maintenance of Remission in Crohn's Disease

    August 2014 in “ Cochrane library
    M Ellen Kuenzig, Ali Rezaie, Cynthia H. Seow, Anthony Otley, A. Hillary Steinhart, Anne M. Griffiths, Gilaad G. Kaplan, Eric I. Benchimol
    Studysummary This study suggests that oral budesonide may not effectively maintain remission in Crohn's disease beyond three months, with minor benefits that are outweighed by increased rates of treatment-related adverse events.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results